Published in PLoS One on May 06, 2016
Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. Oncotarget (2017) 0.75
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 35.41
Hematopoietic stem-cell transplantation. N Engl J Med (2006) 10.45
NKT cells: what's in a name? Nat Rev Immunol (2004) 7.84
Multiplexed particle-based flow cytometric assays. J Immunol Methods (2000) 5.09
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med (1979) 3.59
Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.90
Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity (2013) 2.69
Induction of IgG3 secretion by interferon gamma: a model for T cell-independent class switching in response to T cell-independent type 2 antigens. J Exp Med (1992) 2.47
TH1-TH2: a procrustean paradigm. Nat Immunol (2003) 2.44
Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol (1998) 2.32
Flow cytometry controls, instrument setup, and the determination of positivity. Cytometry A (2006) 2.31
Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. Prog Growth Factor Res (1992) 2.05
Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine (2008) 1.95
Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant (2011) 1.90
Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev (2000) 1.68
Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol (2003) 1.55
Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia (2006) 1.51
Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant (2015) 1.50
Mechanisms of T cell activation by the calcium ionophore ionomycin. J Immunol (1989) 1.48
Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood (2002) 1.39
Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood (2002) 1.39
Cytokine detection by multiplex technology useful for assessing antigen specific cytokine profiles and kinetics in whole blood cultured up to seven days. Cytokine (2006) 1.24
Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6. J Leukoc Biol (2010) 1.23
Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. Tissue Antigens (2013) 1.22
IgG subclass concentrations in certified reference material 470 and reference values for children and adults determined with the binding site reagents. Clin Chem (2003) 1.21
Alloimmunity to human H-Y. Lancet (1976) 1.20
Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma (2003) 1.19
Nonmyeloablative allogeneic immunotherapy for solid tumors. Annu Rev Med (2004) 1.17
Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood (2014) 1.14
The allogeneic graft-versus-cancer effect. Br J Haematol (2009) 1.14
Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. Clin Diagn Lab Immunol (2003) 1.12
How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant (2005) 1.07
Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom? Blood Rev (2012) 1.07
Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion (1996) 1.03
Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases. Bone Marrow Transplant (2007) 1.01
Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics. J Mol Med (Berl) (2001) 0.99
Chimerism patterns of long-term stable mixed chimeras posthematopoietic stem cell transplantation in patients with nonmalignant diseases: follow-up of long-term stable mixed chimerism patients. Biol Blood Marrow Transplant (2013) 0.96
Natural killer T cells in health and disease. Front Biosci (Schol Ed) (2011) 0.94
Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. Biol Blood Marrow Transplant (2014) 0.91
Improved accuracy of acute graft-versus-host disease staging among multiple centers. Best Pract Res Clin Haematol (2014) 0.89
NKT cells: the culprits of sepsis? J Surg Res (2010) 0.88
Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia (2000) 0.87
Coupling the TCR to downstream signalling pathways: the role of cytoplasmic and transmembrane adaptor proteins. Cell Signal (1999) 0.87
Stable mixed donor-donor chimerism after double cord blood transplantation. Int J Hematol (2009) 0.86
Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation. Leukemia (2002) 0.85
Predicting alloreactivity in transplantation. J Immunol Res (2014) 0.84
Measurement of endogenous plasma granulocyte colony-stimulating factor in patients with acquired aplastic anemia by a sensitive chemiluminescent immunoassay. Blood (1996) 0.82
Hemopoietic chimerism following stem cell transplantation. Transfus Apher Sci (2005) 0.82
Occupational status among adult survivors following allo-SCT. Bone Marrow Transplant (2014) 0.80
Characterization of long-term mixed donor-donor chimerism after double cord blood transplantation. Clin Exp Immunol (2010) 0.80
Regulation of lck degradation and refractory state in CD8+ cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (2005) 0.80
Cord blood T cells cultured with IL-7 in addition to IL-2 exhibit a higher degree of polyfunctionality and superior proliferation potential. J Immunother (2013) 0.78
Engraftment and chimerism, particularly of T- and B-cells, in children undergoing allogeneic bone marrow transplantation. Pediatr Transplant (1998) 0.78
Performance characteristics of four immunonephelometric assays for the quantitative determination of IgA and IgM in cerebrospinal fluid. Am J Clin Pathol (2003) 0.77
Long-term sustained mixed chimerism after allogeneic stem cell transplantation in a patient with severe aplastic anemia. Intern Med (2007) 0.76
Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease. Front Immunol (2017) 0.75